anastrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   123 Trials   123 Trials   2738 News 


12345678910111213...4142»
  • ||||||||||  anastrozole / Generic mfg.
    Journal:  Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors. (Pubmed Central) -  Jan 28, 2025   
    Although the combination of onapristone extended-release and anastrozole was well-tolerated, there were no objective responses in patients with progesterone receptor-positive adult-type granulosa cell tumor. Among postmenopausal women with early-stage hormone receptor-positive BC who survived to 6?years after BC diagnosis, longer duration of AI use was not associated with elevated CVD risk.
  • ||||||||||  Journal, Adverse events, Real-world evidence:  Real world pharmacovigilance assessment of drug related macular degeneration risks. (Pubmed Central) -  Jan 12, 2025   
    Lifitegrast, nicotine, and travoprost were associated with the shortest onset times for ocular adverse events...The incidence of drug-related macular degeneration has steadily increased in recent years. This study offers valuable pharmacovigilance insights, highlighting drugs and demographic factors linked to macular degeneration.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Breast Carcinoma Metastasis In Endometrium - A Case Report (Poster area) -  Jan 4, 2025 - Abstract #ESGO2025ESGO_1140;    
    For suspected uterine metastasis, biopsy with histopatologyc and immunohistochemical analysis are necessary to verify tumor origin, guiding treatment. Conclusion Given the rarity of uterine metastasis from breast cancer, further studies are warranted to improve diagnostic and therapeutic strategies.
  • ||||||||||  anastrozole / Generic mfg., cyclophosphamide / Generic mfg., zoledronic acid / Generic mfg.
    Metastatic Breast Cancer To Ovaries And Endometrium: A Rare Case (Poster area) -  Jan 4, 2025 - Abstract #ESGO2025ESGO_1055;    
    Conclusion Breast cancer metastasis to the gynecologic tract is rare, especially when identified in both ovaries and endometrium simultaneously. Attention to clinical symptoms such as vaginal bleeding is important to identify primary carcinoma or metastatic disease as it changes the course of treatment.
  • ||||||||||  Review, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker:  Targeted and cytotoxic inhibitors used in the treatment of breast cancer. (Pubmed Central) -  Dec 18, 2024   
    Patients with ER-positive tumors are treated with 5-10 years of endocrine therapy and chemotherapy. For patients with metastatic breast cancer, standard first-line and follow-up therapy options include targeted approaches such as CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PDL1 immunotherapy, depending on the tumor type and molecular profile.
  • ||||||||||  Tukysa (tucatinib) / Pfizer, Nerlynx (neratinib) / Puma
    Journal:  Quantum DFT analysis and molecular docking investigation of various potential breast cancer drugs. (Pubmed Central) -  Dec 18, 2024   
    In contrast, anastrozole and letrozole show lower binding affinities for HER2 and EGFR due to their simpler structures but are potent aromatase inhibitors, making them effective in treating estrogen receptor-positive (ER-positive) breast cancers. In conclusion, DFT and molecular docking studies affirm the suitability of lapatinib, tucatinib, and neratinib for HER2-positive cancers, while anastrozole and letrozole are effective in ER-positive cancers, emphasizing the role of molecular structure and binding affinity in optimizing cancer treatment strategies.
  • ||||||||||  zoledronic acid / Generic mfg.
    Journal:  Efficacy of a single 5 (Pubmed Central) -  Dec 10, 2024   
    Trial completion date: Dec 2027 --> Aug 2029 | Trial primary completion date: Dec 2024 --> Aug 2028 A single infusion of 5
  • ||||||||||  Trial initiation date:  SWE-Switch: Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer (clinicaltrials.gov) -  Nov 19, 2024   
    P3,  N=3832, Not yet recruiting, 
    All three methods are suitable for their designated purpose, and the choice of the ideal method can be made based on the scope of application, available funds and equipment and desired ecological footprint. Initiation date: May 2024 --> Jan 2025
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Enrollment closed, Trial primary completion date:  TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (clinicaltrials.gov) -  Nov 6, 2024   
    P2,  N=90, Active, not recruiting, 
    In addition, the so far lacking proof of efficacy and safety of PAL in combination with anastrozole or exemestane in 1L and with letrozole in later line was provided by INGE-B. Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> Jun 2025
  • ||||||||||  anastrozole / Generic mfg.
    Evaluating the Accessibility and Affordability of Essential Anticancer Medicines in Pakistan () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2610;    
    Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> Jun 2025 Investment in health systems can improve access to crucial cancer treatments by promoting the indigenous manufacturing of biosimilars and generic alternatives, incorporating Pharmacoeconomics principles for negotiating lower medicine costs, and use in health insurance schemes in alignment with commitments to universal health coverage and cancer care.
  • ||||||||||  Economic Impact of a Pharmacotherapeutic Management Program for Oncological Patients () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1723;    
    The drugs associated were mainly letrozole 9.5%, anastrozole 8.8%, capecitabine 8%, abiraterone 6.1%, temozolamide 4.6% and lenalidomide 4.6%. Clinical follow-up and pharmacotherapeutic management in oncology patients allow for obtaining satisfactory clinical results and a significant economic impact on the health system.
  • ||||||||||  Observational data, Retrospective data, Journal:  Initiation of Oral Endocrine Therapy and Survival Benefit Among Women with Early-Stage Breast Cancer. (Pubmed Central) -  Nov 4, 2024   
    ET initiation and adherence was associated with reduced risk of all-cause (adjusted HR = 0.62, 0.59-0.66; HR = 0.55, 0.53-0.59; respectively) and breast cancer related (adjusted HR = 0.57, 0.50-0.64; HR = 0.41, 0.36-0.47; respectively) mortality compared with noninitiators. Women with early-stage breast cancer who initiate ET and are adherent to treatment may achieve survival benefits compared with noninitiators.
  • ||||||||||  anastrozole / Generic mfg.
    Journal:  Anastrozole improves height outcomes in growing children with congenital adrenal hyperplasia due to 21-OHD. (Pubmed Central) -  Nov 4, 2024   
    Women with early-stage breast cancer who initiate ET and are adherent to treatment may achieve survival benefits compared with noninitiators. Anastrozole decreased the rate of bone maturation and led to improved height outcomes, indicating that anastrozole could have a role as an adjunct therapy in children with CAH and advanced bone age.